Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit i

[tousled1]

SAN ANTONIO, Dec. 15 /PRNewswire/ -- Interim results of the Phase II XeNA (Xeloda in NeoAdjuvant) trial suggest that the combination of oral Xeloda(R) (capecitabine) and Taxotere(R) (docetaxel), with the addition of Herceptin(R) (trastuzumab) in HER2-positive patients, may be an active and well-tolerated neoadjuvant (pre-surgical) treatment option for women with invasive breast cancer. These data were presented today at the San Antonio Breast Cancer Symposium (SABCS).

Full article: http://www.earthtimes.org/articles/show/news_press_release,242937.shtml